Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03912064
Title A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

acute myeloid leukemia

myelofibrosis

myelodysplastic syndrome

chronic myelomonocytic leukemia

myelodysplastic/myeloproliferative neoplasm

Therapies

Ipilimumab

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Brigham and Women's Hospital Recruiting Boston Massachusetts 02115 United States Details
Dana Farber Cancer Institute Recruiting Boston Massachusetts 02115 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field